Ryvu advances romaciclib program as FDA clears AML trial expansion

The regulatory decision follows promising results from RIVER-81

Narayana Health achieves HIMSS AMAM Stage 6, first in Indian subcontinent

Recognition highlights the hospital network’s decade-long investment in analytics and AI-driven healthcare, supporting improved outcomes, efficiency, and affordability.

FUJIFILM reshapes life sciences leadership to accelerate cell therapy and iPSC expansion

Tomoyuki Hasegawa has been appointed CEO of FUJIFILM Biotechnologies California

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Pfizer reports strong mid-stage results for monthly GLP-1 drug berobenatide

The company said data from multiple VESPER studies show the peptide delivered meaningful weight loss, favorable tolerability, and the possibility of a first-in-class monthly injection format

Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

FDA expands Pfizer’s HYMPAVZI approval

Broadening access for children & patients with inhibitor-complicated hemophilia

Mariska Hargitay launches Bristol Myers Squibb's Myeloma Awareness Campaign

The campaign places renewed focus on a disease that remains incurable despite major scientific advances

Lilly’s “triple agonist” drug delivers striking weight loss & broad health gains in late-stage trials

Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems

Our vision is to make genomics as commonplace as BP monitor: Dr. Ramesh Hariharan, Chief Executive Officer, Strand Life Sciences

We are building the bridge between complex molecular data and everyday clinical decisions